<DOC>
	<DOCNO>NCT01212380</DOCNO>
	<brief_summary>RATIONALE : Carfilzomib may stop growth cancer cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose carfilzomib treat patient relapsed refractory chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , prolymphocytic leukemia ( PLL ) .</brief_summary>
	<brief_title>Study Carfilzomib Chronic Lymphocytic Leukemia ( CLL ) , Small Lymphocytic Lymphoma ( SLL ) Prolymphocytic Leukemia ( PLL )</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine dose limit toxicity ( DLT ) maximal tolerate dose ( MTD ) carfilzomib patient relapse refractory Chronic Lymphocytic Leukemia ( CLL ) / Small Lymphocytic Lymphoma ( SLL ) Prolymphocytic Leukemia ( PLL ) . II . To evaluate safety toxicity profile carfilzomib relapse refractory chronic lymphocytic leukemia ( CLL ) /small lymphocytic leukemia ( SLL ) /prolymphocytic leukemia ( PLL ) . SECONDARY OBJECTIVES : I . To evaluate efficacy carfilzomib therapy relapse refractory chronic lymphocytic leukemia ( CLL ) /small lymphocytic leukemia ( SLL ) /prolymphocytic leukemia ( PLL ) justify future phase II study . II . To determine degree duration cellular proteosome inhibition induce carfilzomib relationship pharmacodynamics , response toxicity . III . To determine pharmacokinetics ( plasma cellular ) carfilzomib relationship proteosome inhibition , pharmacodynamics , response , toxicity.IV . To examine effect carfilzomib pharmacodynamic parameter include cytokine , change downstream target include NF-kappa B ( p50/p65 binding ; I-kappa B level , P-I-kappa B level , select target gene ) , p53 ( p53 nuclear level , p53 nuclear binding , select target gene ) , ER stress protein , p73 . OUTLINE : This dose-escalation study carfilzomib.Patients receive carfilzomib intra-venous ( IV ) 30 minute daily , day 1 , 2 , 8 , 9 , 15 , 16 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<criteria>Previously treat patient diagnosis chronic lymphocytic leukemia ( CLL ) , small lymphocytic lymphoma ( SLL ) , prolymphocytic leukemia ( PLL ) NCI Criteria intermediate high risk BCell chronic lymphocytic leukemia ( CLL ) ( Modified Rai stage ) satisfy least one criterion active disease require treatment ; patient history Richter 's transformation eligible evidence chronic lymphocytic leukemia ( CLL ) , &lt; 10 % large cell bone marrow Massive progressive splenomegaly and/or lymphadenopathy ; need cytoreduction stem cell transplant Anemia ( hemoglobin &lt; 11 g/dl ) thrombocytopenia ( platelet &lt; 100 x 10^9/L ) Presence weight loss &gt; 10 % precede 6 month period NCI grade 2 3 fatigue Fevers &gt; 100.5 Â°C night sweat great 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2 month period anticipate doubling time le 6 month Creatinine Clearance ( CrCl ) &gt; 15mL/min Alanine aminotransferase ( ALT ) &lt; 3X upper limit normal ( ULN ) Bilirubin = &lt; 2 time upper limit normal , unless disease relate Platelets &gt; = 20 x 10^9/L absence active bleeding Patients must ECOG ( Eastern Cooperative Oncology Group ) performance status = &lt; 2 Patients must secondary cancer result life expectancy &lt; 2 year would confound assessment toxicity study Patients racial/ethnic group eligible study meet eligibility criterion outline Patients must provide write informed consent Absence previously treat chronic lymphocytic leukemia ( CLL ) Female subject pregnant breastfeeding ; woman childbearing potential men must agree use adequate contraception prior study entry , duration study participation , 30 day follow study completion ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; confirmation subject pregnant must establish negative serum human chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening ; pregnancy test require postmenopausal surgically sterilized woman Patients congestive heart failure ( CHF ) pretreatment hydration would prohibitive ; New York Heart Association ( NYHA ) Class III/IV CHF exclude Patients treatment chronic lymphocytic leukemia ( CLL ) within 2 week , although palliative steroid acceptable Patient unable give write informed consent Failure recover toxicity previous radiotherapy chemotherapy grade 1 Patients active infection require intravenous ( IV ) antibiotic/antiviral therapy eligible entry onto study resolution infection ; patient prophylactic antibiotic antiviral acceptable Patients previously take bortezomib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Small Lymphocytic Lymphoma</keyword>
	<keyword>Prolymphocytic Leukemia</keyword>
</DOC>